Eqis Capital Management Inc. decreased its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 4.6% during the 3rd quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 3,032 shares of the biopharmaceutical company’s stock after selling 147 shares during the quarter. Eqis Capital Management Inc.’s holdings in Regeneron Pharmaceuticals were worth $1,356,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also made changes to their positions in REGN. BlackRock Inc. lifted its position in Regeneron Pharmaceuticals by 3,331.5% in the 1st quarter. BlackRock Inc. now owns 6,146,861 shares of the biopharmaceutical company’s stock valued at $2,381,971,000 after acquiring an additional 5,967,733 shares in the last quarter. Janus Henderson Group PLC lifted its position in Regeneron Pharmaceuticals by 15,495.4% in the 2nd quarter. Janus Henderson Group PLC now owns 1,562,970 shares of the biopharmaceutical company’s stock valued at $767,637,000 after acquiring an additional 1,552,948 shares in the last quarter. Jennison Associates LLC lifted its position in Regeneron Pharmaceuticals by 74.1% in the 2nd quarter. Jennison Associates LLC now owns 1,292,863 shares of the biopharmaceutical company’s stock valued at $634,977,000 after acquiring an additional 550,247 shares in the last quarter. Janus Capital Management LLC lifted its position in Regeneron Pharmaceuticals by 58.5% in the 1st quarter. Janus Capital Management LLC now owns 1,317,162 shares of the biopharmaceutical company’s stock valued at $510,406,000 after acquiring an additional 486,119 shares in the last quarter. Finally, FMR LLC lifted its position in Regeneron Pharmaceuticals by 6.3% in the 2nd quarter. FMR LLC now owns 7,039,884 shares of the biopharmaceutical company’s stock valued at $3,457,569,000 after acquiring an additional 416,192 shares in the last quarter. 67.40% of the stock is currently owned by institutional investors and hedge funds.

In related news, major shareholder Sanofi bought 166,415 shares of the company’s stock in a transaction that occurred on Thursday, August 24th. The stock was purchased at an average price of $480.93 per share, for a total transaction of $80,033,965.95. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Charles A. Baker sold 2,000 shares of the company’s stock in a transaction on Friday, September 29th. The stock was sold at an average price of $450.00, for a total transaction of $900,000.00. Following the transaction, the director now owns 11,000 shares of the company’s stock, valued at approximately $4,950,000. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 89,468 shares of company stock valued at $42,312,448. 10.80% of the stock is owned by company insiders.

Shares of Regeneron Pharmaceuticals, Inc. (REGN) traded down 2.16% on Friday, reaching $431.43. 308,067 shares of the company’s stock traded hands. Regeneron Pharmaceuticals, Inc. has a 52-week low of $325.35 and a 52-week high of $543.55. The stock has a market cap of $45.75 billion, a price-to-earnings ratio of 43.28 and a beta of 1.62. The firm’s 50-day moving average is $452.90 and its 200-day moving average is $456.40.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings data on Thursday, August 3rd. The biopharmaceutical company reported $4.17 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $2.67 by $1.50. The firm had revenue of $1.47 billion during the quarter, compared to analysts’ expectations of $1.36 billion. Regeneron Pharmaceuticals had a net margin of 22.05% and a return on equity of 25.58%. The company’s revenue for the quarter was up 21.2% compared to the same quarter last year. During the same period in the prior year, the company posted $2.82 earnings per share. Analysts anticipate that Regeneron Pharmaceuticals, Inc. will post $14.94 EPS for the current fiscal year.

Several brokerages recently weighed in on REGN. J P Morgan Chase & Co reaffirmed a “hold” rating on shares of Regeneron Pharmaceuticals in a research report on Tuesday, August 15th. Zacks Investment Research raised shares of Regeneron Pharmaceuticals from a “hold” rating to a “strong-buy” rating and set a $540.00 price target on the stock in a research report on Wednesday, August 9th. Leerink Swann reaffirmed an “outperform” rating and issued a $580.00 price target (up previously from $573.00) on shares of Regeneron Pharmaceuticals in a research report on Wednesday, August 9th. Robert W. Baird lowered shares of Regeneron Pharmaceuticals from a “neutral” rating to an “underperform” rating and set a $408.00 price objective for the company. in a research note on Tuesday, August 8th. Finally, Goldman Sachs Group, Inc. (The) reiterated a “neutral” rating and issued a $472.00 price objective (up previously from $469.00) on shares of Regeneron Pharmaceuticals in a research note on Wednesday, August 9th. Four equities research analysts have rated the stock with a sell rating, thirteen have assigned a hold rating, twelve have assigned a buy rating and one has assigned a strong buy rating to the company. The company presently has an average rating of “Hold” and an average target price of $489.92.

ILLEGAL ACTIVITY WARNING: This piece was first published by Daily Political and is the property of of Daily Political. If you are reading this piece on another domain, it was copied illegally and reposted in violation of United States and international copyright & trademark law. The correct version of this piece can be accessed at https://www.dailypolitical.com/2017/10/20/eqis-capital-management-inc-sells-147-shares-of-regeneron-pharmaceuticals-inc-regn.html.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases.

Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN).

Institutional Ownership by Quarter for Regeneron Pharmaceuticals (NASDAQ:REGN)

Receive News & Ratings for Regeneron Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.